Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjmed.2010.11.002PMID 21194578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.

  2011cited by this paper
• Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

  2010cited by this paper
• Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes

  2010cited by this paper
• Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

  2010cited by this paper
• Pharmacological Characterization of Human Incretin Receptor Missense Variants

  2010cited by this paper
• Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

  2010cited by this paper
• Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

  2010cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

  2010cited by this paper
• The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

  2010cited by this paper
• Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

  2010cited by this paper
• GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis.

  2010cited by this paper
• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  2010cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes

  2009cited by this paper
• Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

  2009cited by this paper
• Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

  2009cited by this paper
• Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

  2009cited by this paper
• Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• DPP‐IV inhibition enhances the antilipolytic action of NPY in human adipose tissue

  2009cited by this paper
• The contribution of incretin hormones to the pathogenesis of type 2 diabetes.

  2009cited by this paper
• Beneficial Endocrine but adverse Exocrine effects of Sitagliptin in the HIP rat model of Type 2 Diabetes, interactions with Metformin.

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

  2009cited by this paper
• Exogenous Glucose–Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes

  2009cited by this paper
• Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes

  2009cited by this paper
• Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects

  2009cited by this paper
• Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

  2009cited by this paper
• Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Unraveling the science of incretin biology.

  2009cited by this paper
• Impact of Sitagliptin on Markers of &bgr;-cell Function: A Meta-Analysis

  2009cited by this paper
• Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

  2009cited by this paper
• Glucagon‐like peptide‐1 in type 2 diabetes: the β‐cell and beyond

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

  2008cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

  2008cited by this paper
• Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2008cited by this paper
• Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

  2008cited by this paper
• Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes *

  2008cited by this paper
• Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

  2008cited by this paper
• Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

  2008cited by this paper
• Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.

  2008cited by this paper
• Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance

  2008cited by this paper
• Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea *

  2008cited by this paper
• Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia

  2007cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

  2007cited by this paper
• Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.

  2007cited by this paper
• Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes*

  2007cited by this paper
• Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

  2007cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007cited by this paper
• Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors)

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes

  2006cited by this paper
• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein.

  2006cited by this paper
• Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes

  2006cited by this paper
• Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

  2006cited by this paper
• Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.

  2006cited by this paper
• Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

  2006cited by this paper
• Incretins and the development of type 2 diabetes

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

  2006cited by this paper
• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.

  2005cited by this paper
• Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

  2005cited by this paper
• The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1

  2005cited by this paper
• Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?

  2005cited by this paper
• GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats.

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

  2005cited by this paper
• Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

  2005cited by this paper
• Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

  2005cited by this paper
• What do we know about the secretion and degradation of incretin hormones?

  2005cited by this paper
• Glucagon-Like Peptide 1 Regulates Sequential and Compound Exocytosis in Pancreatic Islet β-Cells

  2005cited by this paper
• Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells.

  2005cited by this paper
• The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.

  2005cited by this paper
• The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.

  2004cited by this paper
• Neural regulation of glucagon-like peptide-1 secretion in pigs.

  2004cited by this paper
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004cited by this paper

• Linagliptin Attenuates the Adverse Effects of a High-Sugar Diet on Insulin Sensitivity, Hippocampal Oxidative Stress, and Cognitive Function in Rats.

  2026cites this paper
• Long‐Term Effectiveness of Once‐Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real‐World Study

  2025cites this paper
• Diabesidad: concepto e implicancias

  2025cites this paper
• Strategies to Enhance the Therapeutic Efficacy of GLP‐1 Receptor Agonists through Structural Modification and Carrier Delivery

  2025cites this paper
• Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy

  2025cites this paper
• Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases

  2025cites this paper
• A Comprehensive Meta-analysis of Efficacy, Cardiovascular Protection, and Emerging Therapeutic Innovations of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus

  2025cites this paper
• Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models

  2024cites this paper
• Synthetic exendin-4 disrupts responding to reward predictive incentive cues in male rats

  2024cites this paper
• The In Vitro Inhibitory Activity of Pacaya Palm Rachis versus Dipeptidyl Peptidase-IV, Angiotensin-Converting Enzyme, α-Glucosidase and α-Amylase

  2024cites this paper
• Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies

  2024cites this paper
• Terpenoids as potential phytoconstituent in the treatment of diabetes: From preclinical to clinical advancement.

  2024cites this paper
• Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review.

  2024cites this paper
• Effects of glucagon‑like peptide‑1 receptor agonists on fracture healing in a rat osteoporotic model

  2023cites this paper
• Kajian Rute Alternatif Pemberian Liraglutide dalam Penanganan Diabetes dan Obesitas

  2023cites this paper
• Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics

  2022cites this paper
• Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases

  2022cites this paper
• Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus

  2022cites this paper
• Biochemical Investigation of Inhibitory Activities of Plant-Derived Bioactive Compounds Against Carbohydrate and Glucagon-Like Peptide-1 Metabolizing Enzymes

  2022cites this paper
• Diabetic bone regeneration with nanoceria-tailored scaffolds by recapitulating cellular microenvironment: Activating integrin/TGF-β co-signaling of MSCs while relieving oxidative stress.

  2022cites this paper
• Impact of Lycium barbarum polysaccharide on the expression of glucagon-like peptide 1 in vitro and in vivo.

  2022cites this paper
• A comprehensive review on the glucoregulatory properties of food-derived bioactive peptides

  2022cites this paper
• Compendious Review on Adipokines of Corpulence

  2022cites this paper
• Possible mechanisms and molecular signaling of incretins against the development of type 2 diabetes mellitus.

  2022cites this paper
• Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study

  2022cites this paper
• Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study

  2022cites this paper
• Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment

  2022cites this paper
• Sleeve-Plus Procedures in Asia: Duodenojejunal Bypass and Proximal Jejunal Bypass

  2021cites this paper
• Incretins in the Therapy of Diabetic Kidney Disease

  2021cites this paper
• Glucagon-like peptide-1 regulation by food proteins and protein hydrolysates

  2021cites this paper
• Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity

  2021cites this paper
• Therapeutic Dilemma in personalized medicine.

  2021cites this paper
• Regulation of food intake by intestinal hormones in brain

  2021cites this paper
• Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus

  2020cites this paper
• Adipokines

  2020cites this paper
• Evaluation of Hypoglycaemic Effects of Dipeptidyl Peptidase–4 Inhibitors and Biguanide on Type-2 Diabetic subjects: A six months trial

  2020cites this paper
• High protein diet leads to prediabetes remission and positive changes in incretins and cardiovascular risk factors.

  2020cites this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cites this paper
• Phytochemicals in Garlic Extract Inhibit Therapeutic Enzyme DPP-4 and Induce Skeletal Muscle Cell Proliferation: A Possible Mechanism of Action to Benefit the Treatment of Diabetes Mellitus

  2020cites this paper
• On Meal Effects and DPP-4 Inhibition Islet- and Incretin Hormones in Health and Type 2 Diabetes

  2020cites this paper
• Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile

  2020cites this paper
• Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study

  2020cites this paper
• Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies

  2020cites this paper
• Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies

  2020cites this paper
• Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes

  2020cites this paper
• Direct suppression of human islet dedifferentiation, progenitor genes, but not epithelial to mesenchymal transition by liraglutide

  2020cites this paper
• The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation

  2020cites this paper
• Total synthesis and absolute structure of N55, a positive modulator of GLP-1 signaling.

  2020cites this paper
• Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo

  2020cites this paper
• Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects

  2020cites this paper
• Acute Effects of Nutritive and Non-Nutritive Sweeteners on Postprandial Blood Pressure

  2019cites this paper
• Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis.

  2019cites this paper
• Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets

  2019cites this paper
• Screening for Insulin-Like/Mimetic Drugs Using Lower Eukaryotes

  2019influential citation
• Fighting type-2 diabetes: present and future perspectives.

  2019cites this paper
• Incremental effect of liraglutide on traditional insulin injections in rats with type 2 diabetes mellitus by maintaining glycolipid metabolism and cardiovascular function.

  2019cites this paper
• Zinc-induced activation of GPR39 regulates glucose homeostasis through glucose-dependent insulinotropic polypeptide secretion from enteroendocrine K-cells

  2019cites this paper
• The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship.

  2019cites this paper
• Beneficial long‐term antidiabetic actions of N‐ and C‐terminally modified analogues of apelin‐13 in diet‐induced obese diabetic mice

  2018influential citation
• Rôle de la synthèse des miARN par le tissu adipeux dans les pathologies de vieillissement

  2018cites this paper
• Incretin and Cardiovascular Effects of Weight Loss and Remission of Prediabetes

  2018influential citation
• Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis

  2018cites this paper
• Immune and metabolic alterations in first episode psychosis (FEP) patients.

  2018cites this paper
• Targeted intestinal delivery of incretin secretagogues—towards new diabetes and obesity therapies

  2018cites this paper
• Vildagliptin: ten years in the service for type 2 diabetes mellitus patients. The journey of discovery, innovation and success in clinical practice

  2018cites this paper
• Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis

  2018influential citation
• A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

  2018cites this paper
• Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study

  2018cites this paper
• Clinical pharmacology of glucagon-like peptide-1 receptor agonists

  2018cites this paper
• Distribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract.

  2018cites this paper
• Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors

  2018cites this paper
• Role and regulation of microRNAs in adipose tissue during aging

  2018cites this paper
• Liraglutide regulates the viability of pancreatic &agr;‐cells and pancreatic &bgr;‐cells through cAMP‐PKA signal pathway

  2018cites this paper
• Beyond glycaemic control: A cross‐over, double‐blinded, 24‐week intervention with liraglutide in type 1 diabetes

  2018cites this paper
• Liraglutide reduces hepatic glucolipotoxicity-induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats

  2018cites this paper
• A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

  2018cites this paper
• Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis.

  2018cites this paper
• Reactive hypoglycaemia with seizure following intraduodenal glucose infusion in a patient with type 2 diabetes

  2017cites this paper
• Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG7697 after single subcutaneous administration in healthy subjects

  2017cites this paper
• Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.

  2017cites this paper
• Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.

  2017cites this paper
• Fármacos para o tratamento do diabetes tipo II: Uma visita ao passado e um olhar para o futuro

  2017cites this paper
• Anti-diabetic medications: How to make a choice?

  2017cites this paper
• Variable anti-edema and anti-granuloma effects of liraglutide and teneligliptin on experimental Wistar albino rat inflammatory models

  2017cites this paper
• Spatiotemporal Modeling of Triggering and Amplifying Pathways in GLP-1 Secreting Intestinal L Cells.

  2017cites this paper
• Feline diabetes mellitus . Aspects on epidemiology and pathogenesis

  2017cites this paper
• Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance

  2017influential citation
• Recent advances in understanding/managing type 2 diabetes mellitus

  2017cites this paper
• Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope.

  2017cites this paper
• Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies

  2017cites this paper
• Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

  2017cites this paper
• Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

  2017cites this paper
• DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity

  2017cites this paper
• Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

  2017cites this paper
• [Delphi consensus on the individualised management of diabetes in primary care. ICANDAP study].

  2017cites this paper
• In Vivo Models for Incretin Research: From the Intestine to the Whole Body

  2016cites this paper
• Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.

  2016cites this paper
• Antidiabetic properties of centella asiatica in type II diabetic rats.

  2016cites this paper
• Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

  2016influential citation
• Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model

  2016cites this paper